Demyelination is a key component in the pathogenesis of many neurological disorders. Transplantation of myelinating cells may offer a therapeutic approach to restore neurological function in these diseases. Recent findings suggest that pluripotent embryonic stem (ES) cells can serve as an unlimited donor source for neural transplantation. The clinical application of ES cells for myelin repair will depend critically on the ability to enrich oligodendroglial progenitors in high purity. Combining controlled differentiation in the presence of growth factors and genetic lineage selection, we devised a cell culture protocol yielding highly purified oligodendrocyte progenitors. Murine ES cell clones stably transfected with a construct encoding the β-galactosidase-neomycine phosphotransferase fusion protein (βgeo) under control of the 2′3′-cyclic nucleotide 3′-phosphodiesterase (CNP) promoter were differentiated into bipotential glial precursors. Subsequent induction of a CNP-positive stage and selection in neomycine resulted in a homogenous cell population with a pre-oligodendrocyte phenotype. The selected cells continued to proliferate in the presence of FGF-2 and PDGF and, upon growth factor withdrawal, differentiated into mature galactocerebroside (GalC)-positive oligodendrocytes. Transplantation studies in myelin-deficient (md) rats indicate that ES cell-derived oligodendrocyte progenitors generated with this method may serve as an attractive donor source for myelin repair.
of demyelinating diseases (9, 10) . Although OPs, SCs, and OECs could, in principle, be prepared from the same patient, such an approach might not always be desirable. In myelin disorders arising from a cell-autonomous oligodendroglial defect (such as Pelizaeus-Merzbacher disease), transplantation of autologous OPs would re-introduce a faulty cell population. In diseases resulting from an autoimmune response to distinct oligodendrocyte/myelin antigens, autologous OPs, too, would remain susceptible to the autoimmune response.
Neural stem cells (11) (12) (13) , continuously growth factor-expanded glial progenitors (14) , and oligodendroglial cell lines such as CG-4 (15, 16) have been considered as alternative donor sources for remyelinating transplants. Although these cell types offer the advantage of in vitro expandability, their generation still depends on access to CNS tissue. In addition, their extensive in vitro proliferation bears the risk of karyotype instability and transformation (17) .
The availability of embryonic stem (ES) cells has provided new prospects for generating tissuespecific stem and progenitor cells in virtually unlimited numbers in vitro (18) . ES cells are derived from the inner cell mass of blastocyst-stage embryos and can be stably propagated as a continuously self-renewing homogeneous cell population capable of generating all somatic tissues and cell types (19, 20) . Due to their pluripotency, their potential for limitless self-renewal and their amenability to genetic modification and gene targeting, ES cells are widely considered as the most versatile donor source for cell and tissue repair (18, 21) . The therapeutic application of ES cells requires the generation of highly purified and specialized cell populations and the elimination of undifferentiated embryonic stem cells, which may form tumors in the transplant recipient (22, 23) .
In this study, we explore a new strategy for the enrichment and isolation of ES cell-derived OPs. Specifically, growth factor controlled differentiation of ES cells into bipotential glial precursors was combined with a subsequent oligodendrocyte-specific lineage selection step. Using a selection construct carrying a neomycine resistance gene under control of the murine oligodendrocyte-specific CNP promoters I and II, we demonstrate that this strategy can be used to prepare highly purified cultures of proliferating OPs capable of generating myelinating oligodendrocytes in vivo.
MATERIALS AND METHODS

Culture, transfection, and differentiation of ES cells
Mouse ES cells (line CJ7, kindly provided by T. Gridley; ref 24) were electroporated with the pCNP-βgeo plasmid (100 µg) and a hygromycine resistance plasmid (pPGK-Hyg, 20 µg), using a Bio-Rad gene pulser (230 V, 500 µF). The pCNP-βgeo plasmid carries the gene for the fusion protein βgeo under control of the murine oligodendrocyte-specific CNP promoters I and II (25) . Selection of hygromycine-resistant ES cell clones was performed with 400 µg/ml hygromycine on multiple-drug-resistant murine embryonic fibroblasts (MEFs) prepared from the DR-4 mouse strain (26) . ES cell clones were expanded on γ-irradiated MEFs in the presence of 100 U/ml leukemia inhibitory factor (LIF; Chemicon, Hofheim, Germany). ES cell differentiation was performed as described previously (27) . Briefly, ES cells were passaged and propagated on gelatine-coated dishes (0.1%, Sigma, Steinheim, Germany) for 2 days to eliminate MEFs. The cells were then transferred to bacterial culture dishes to allow for embryoid body (EB) formation and initiation of differentiation. Four-day-old EBs were plated in defined ITSFn medium containing 5 µg/ml insulin (Intergene, Purchase, NY), 50 µg/ml human apo-transferrin (Intergene), 30 nM sodium selenite (Sigma), and 2.5 µg/ml fibronectin (Life Technologies, Karlsruhe, Germany). This medium has been shown to favor the survival of neuroepithelial cells (28) . After 5 days, cells were triturated to a single cell suspension and further propagated on polyornithine-coated dishes (15 µg/ml, Sigma) in the presence of FGF-2 (10 ng/ml), which permits the proliferation of multipotential neural precursors. To obtain glial precursors, ES cellderived neural precursors were again dissociated and cultured in the presence of FGF-2 (10 ng/ml) and EGF (20 ng/ml) followed by proliferation in medium containing FGF-2 and PDGF (10 ng/ml). All growth factors were purchased from R&D Systems (Wiesbaden, Germany). To prepare for lineage selection, glial precursors grown in the presence of FGF-2 and PDGF were initiated to differentiate by a 4 day growth factor withdrawal in the presence of 3,3,5-triiodothyronine hormone (T3, 30 nM, Sigma). The cells were then cultured for 2 days in medium containing 0.5% fetal calf serum (FCS, Biochrome, Berlin, Germany), T3, FGF-2, and PDGF. Cells propagated in this medium were exposed to G418 (Gibco-BRL, Karlsruhe, Germany, 180-200 µg/ml) for 2-3 days.
PCR analysis
Hygromycine-resistant ES cell clones were screened for the expression of CNP-βgeo by PCR analysis using 0.5 µg genomic DNA and primers amplifying a 313 bp sequence corresponding to the CNP promoter and the βgeo region (forward: 5′-ATC CTT GGA GCC AGA GAC TAA G-3′; reverse: 5′-GCC ATG TCA CAG ATC ATC AAG C-3′). The PCR reaction was performed according to Chandross et al. (25) .
Bromodeoxyuridine incorporation and detection
After lineage selection, cells cultured in the presence of FGF-2 and PDGF were labeled with 10 µM bromodeoxyuridine (BrdU, Sigma) for 24, 48, and 72 h. The cells were fixed with 4% paraformaldehyde (PFA), permeabilized in 70% ethanol for 10 min, incubated in 6 N HCL and 1% Triton X-100 (15 min, room temperature), and then incubated in 0.1 M sodium borate (in PBS and 1% Triton X-100) for 10 min. The cells were pretreated with 5% normal goat serum and 1% Triton X-100 for 30 min and subsequently incubated with a monoclonal antibody to BrdU (1:33, Becton-Dickinson, Heidelberg, Germany). Signal was visualized using a rhodamineconjugated antibody to mouse IgG (1:100, Jackson ImmunoResearch Laboratories, West Grove, PA). For quantification, cell nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI, Sigma).
Immunocytochemical analysis
Cell cultures were fixed with 4% PFA for 10 min at room temperature. After being washed in PBS, cells were blocked with 5% normal goat serum in PBS for 15 
Protein extraction and Western blot analysis
Sciatic and brachial nerves were dissected from CD-1 mice, and total protein lysates were homogenized by sonication in ice-cold lysis buffer (50 mM Tris-HCl, pH 8.0, 120 mM NaCl, 5 mM EDTA, 0.5% NP-40, 100 mg/ml phenylmethylsulfonyl fluoride, 2 µg/ml aprotinin, 10 µg/ml leupeptin). The same lysis buffer was used for protein extraction from purified ES cellderived oligodendroglial cell cultures. Total protein concentrations were quantified with a Bradford assay (Bio-Rad, Cambridge, MA). For immunoblot analysis, 25 µg of protein extract were separated on 10-12% SDS-polyacrylamide gels and electroblotted onto nitrocellulose membranes (Amersham Bioscience, Freiburg, Germany). Equal loading was confirmed by Ponceau S staining. The blots were blocked with 5% fat-free milk powder in PBS/0,05%Tween 20 and probed with primary antibodies to CNP (mouse IgG, 1:2000, Abcam, Cambridge, UK), Krox20 (rabbit IgG, 1:100, Covance, Berkeley, CA), and β-gal (rabbit IgG, 1:3000, Abcam). Signals were visualized with secondary horseradish peroxidase-conjugated antibodies and an enhanced luminol solution (SuperSignal System, Pierce, Rockford, IL).
Cell transplantation, tissue processing, and analysis
Cell transplantation into the spinal cord of early postnatal (P4-P6) myelin-deficient rats (md rats; kindly provided by Ian Duncan, University of Wisconsin, Madison, WI) was performed as described previously (27) . Briefly, cells proliferating in FGF-2 and PDGF were harvested with trypsin-EDTA (Sigma, 0.5 mg/ml), followed by treatment with soybean trypsin inhibitor (Sigma, 0.5 mg/ml). They were concentrated in Hanks' buffered salt solution to 75,000 cells/µl. A laminectomy was performed at the thoracolumbar transition. With the use of a glass micropipette with a 50-75 µm fire-polished orifice, 1 µl of the cell suspension was carefully injected over a 5 min period into the dorsal columns. Postoperatively, engrafted animals received daily injections of cyclosporine (10 mg/kg). Seven to fifteen days after transplantation, the recipients were anesthetized with pentobarbital and perfused with 4% paraformaldehyde in PBS. The transplanted spinal cord segments were removed, rinsed in PBS, and cryoprotected in 30% sucrose over night. To identify engrafted oligodendrocytes, 50 µm cryostat sections were subjected to DNA in situ hybridization with a digoxigenin-labeled probe to mouse satellite DNA as described previously (29) . DNA in situ hybridization was combined with an anti-PLP immunofluorescence analysis. To account for antigen destruction and signal degradation during DNA in situ hybridization, bound antibody was visualized after the hybridization procedure, using a fluorescein tyramide reagent (1:50, NEN, Boston, MA). Transplanted donor cells were detected in five out of five grafted animals. All procedures were performed in accordance with institutional guidelines.
X-gal histochemistry
Cell cultures were permeabilized for 20-30 min in PBS containing 2 mM MgCl 2 , 1.25 mM EGTA, 0.01% Na-deoxycholate, and 0.02% NP-40. For detection of β-gal activity, cells were incubated overnight at 37°C in the same buffer supplemented with 5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 , and 1 mg/ml X-gal (5-brom-4-chloro-3-indonyl-β-D-galactopyranoside, Sigma).
RESULTS
Efficient oligodendroglial lineage selection using the CNP-βgeo transgene
To provide a basis for lineage selection, undifferentiated mouse ES cells were cotransfected with a construct encoding βgeo under control of the murine CNP promoter and a hygromycine resistance plasmid. The hygromycine resistance gene was expressed from the constitutively active PGK promoter, which allowed the first selection at the ES cell level. Ninety-six hygromycine-resistant clones were obtained and screened for the expression of CNP-βgeo by PCR analysis of genomic DNA (data not shown). Of these, 36 positive clones were subjected to controlled in vitro differentiation into bipotential glial precursors (Fig. 1) . After aggregation to embryoid bodies, spontaneously differentiating neuroepithelial cells were selected in ITSFn medium. Multipotent neural precursors were induced to proliferate in the presence of FGF-2, and the cells were subsequently shifted into a glial precursor fate by sequential propagation in FGF-2/EGF and FGF-2/PDGF as described previously (27) . After growth factor-induced differentiation, up to 40% of the glial precursors derived from the transfected ES cell clones showed β-gal staining. Glial precursors derived from nine clones with the highest β-gal expression levels were further subjected to neomycine selection for CNP-βgeo-expressing cells. To enable efficient lineage selection, we developed a specific sequence of culture conditions that induce and stabilize a CNP-positive fate while avoiding postmitotic terminal differentiation ( Fig.  1 ; stages a-c). Glial precursors proliferating in the presence of FGF-2 and PDGF (Fig. 1, stage a) were subjected to a temporary, 4 day growth factor withdrawal in the presence of T3, a hormone known to facilitate the differentiation of oligodendrocytes (30) . This predifferentiation step resulted in a population of small, process-bearing cells with condensed cell bodies and flat cells with an astrocyte-like morphology (Fig. 1, stage b) . These cells were further differentiated for 2 days in serum-containing medium in the presence of FGF-2, PDGF, and T3 (Fig. 1, stage c) . Subsequently, the cultures were subjected to neomycine selection in the presence of FGF-2 and PDGF for additional 2-3 days (Fig. 1, stage d) . During this time the cells with flat, astrocytic morphology died, leaving a homogenous population of bipolar cells with poorly branched processes characteristic of oligodendroglial progenitor cells. Glial precursors derived from wild-type ES cells did not survive this purification process, confirming the specificity of the CNPβgeo-based selection. After lineage selection and an additional day of culturing in the presence of PDGF and FGF-2, the selected cells showed robust X-gal staining (Fig. 2B) . Immunofluorescence analysis showed that 96 ± 7% of the selected cells coexpress CNP and β-gal ( Fig. 2A and C) . These data demonstrate that the CNP-βgeo transgene permits efficient selection of CNP-expressing cells from differentiating ES cells.
The selected cell population exhibits a pre-oligodendrocyte phenotype
We next examined the developmental stage and the differentiation potential of the selected cell population. Of the cells obtained by CNP-based lineage selection, 80 ± 7% still displayed nestin immunoreactivity ( Fig. 2A and D) . Nestin has been shown to be expressed in proliferating OPs but is downregulated in differentiated oligodendrocytes (31) . A large fraction (88±9%) also expressed the polysialylated or embryonic form of the neural cell adhesion molecule NCAM (PSA-NCAM) ( Fig. 2A and E) . In addition to the expression of nestin and PSA-NCAM, 95 ± 6% of the cells displayed immunoreactivity to the A2B5 antibody, which recognizes gangliosides expressed by dividing OPs in vitro (32; Fig. 2A and F) . A fraction of 78 ± 10% was found to be positive for the O4 antigen, indicating incipient oligodendroglial differentiation ( Fig. 2A and G) . Surprisingly, only a small subset (10±6%) of the selected cells expressed NG-2 ( Fig. 2A and H) , an antigen typically detected in precursors to oligodendrocytes (33-35). A low rate of spontaneous differentiation into more mature oligodendrocytes was suggested by the presence of GalC-positive cells (Fig. 2A) . This marker of early oligodendrocyte differentiation was found in 9 ± 4% of cells. The selected population also comprised a small fraction of GFAP-positive cells (3±3%; Fig. 2A and I) . Since CNP is expressed in SCs, we also studied the expression of the transcription factor Krox20 and the myelin protein P0, i.e., markers characteristic of a SC fate (36-38). Immunocytochemical analysis using Krox20-and P0-specific antibodies failed to detect any immunoreactive cells among the selected population (data not shown). Western blot analyses confirmed the absence of Krox20 whereas CNP and the βgeo fusion protein were strongly expressed in the selected cells (Fig. 2J ). These observations indicate that the in vitro differentiation protocol employed does not provide sufficient precursors for a CNP-βgeo-based selection of ES cell-derived SCs. Immunocytochemical studies with an antibody to β-III tubulin further confirmed the absence of neurons in the selected cell populations. Taken together, the coexpression of CNP with nestin, PSA-NCAM, and A2B5, i.e., markers typically associated with a neural precursor stage, indicates that the majority of the selected cells represents an early preoligodendrocyte phenotype (33).
CNP promoter-based lineage selection yields a mitotically active oligodendroglial cell population
We next asked whether the selected cells can be maintained in a proliferative stage. BrdU incorporation was analyzed after selection with G418 for 2-3 days, followed by a culture period of 24, 48, and 72 h in the presence of the mitogens FGF-2 and PDGF (Fig. 3) . The selected cells continued to proliferate with a doubling time of ~72 h, confirming that they still represent precursors rather than postmitotic oligodendrocytes. Growth factor withdrawal for 3 days induced differentiation into a more mature, GalC-positive phenotype in 80 ± 7% of the population (Fig. 4A) . The differentiated cells acquired a complex oligodendroglial morphology with intricately ramified multipolar processes (Fig. 4B ). These data demonstrate that CNP promoter-based lineage selection of in vitro predifferentiated ES cells yields a mitotic glial precursor cell population amenable to FGF-2/PDGF-mediated proliferation and growth factor withdrawal-induced differentiation.
The selected cell population exhibits a myelinating phenotype in vivo
To study whether the selected ES cell-derived OPs can, in principle, generate myelinating oligodendrocytes in vivo, we performed a first set of transplant experiments in the spinal cord of 4-6-day-old md rats. This mutant develops severe CNS hypomyelination due to a point mutation in the X-linked PLP gene (39). The phenotype of these rats resembles the human myelin disorder Pelizaeus Merzbacher disease, which is also associated with aberrations in the PLP gene (40). Because md rats lack endogenous PLP-positive myelin, they represent attractive transplant recipients for studying donor-derived myelination (41). Two weeks after transplantation, the engrafted cells, indeed, had formed PLP-positive myelin internodes (Fig. 5A) . Double labeling of PLP-immunolabeled cells with a mouse-specific DNA probe confirmed the donor origin of the engrafted cells ( Fig. 5B and C) . Although further transplantation studies are required to fully analyze the in vivo differentiation and myelination capacity of CNP-βgeo-selected ES cellderived oligodendrocytes, these data demonstrate the myelinogenic potential of the purified cell population.
DISCUSSION
The results of this study demonstrate that the combination of growth factor-controlled ES cell differentiation and CNP promoter-based lineage selection permits the in vitro generation of highly purified OPs. The purified cell populations remain proliferative in vitro and, upon transplantation, generate myelinating oligodendrocytes in vivo.
Previous studies have shown that murine ES cells induced to differentiate with retinoic acid give rise to neurons and glia (42-45). In addition, defined culture conditions have been employed to enrich proliferating neuroepithelial precursors from differentiating ES cell cultures without the use of retinoic acid (28, 46) . Li et al. (47) used genetic lineage selection as a tool to derive multipotent neural precursors from ES cells carrying the βgeo transgene targeted to the Sox2 locus. More recently, cell culture protocols have been established to enrich murine ES cellderived neurons of defined neurotransmitter phenotypes, including dopaminergic neurons (48) (49) (50) . A continuously increasing number of publications indicate that the in vitro differentiation of neural precursors can be translated from mouse to human ES cells (51) (52) (53) (54) (55) .
In comparison to the strong interest in neuronal differentiation, the generation of ES cell-derived glia has received only limited attention. A study by Billon et al. (56) indicates that the stepwise transition of an ES cell-derived neural precursor cell to differentiated oligodendroglia closely resembles normal oligodendrocyte development in vivo. Mujtaba et al. (57) isolated A2B5-expressing glial precursors from differentiating mouse ES cell cultures by immunopanning. These cells expressed nestin, were negative for markers of postmitotic neurons and glia, and had the potential to differentiate into oligodendrocytes and astrocytes. Results by Liu et al. (58) imply that sphere cultures composed of glial cells can be derived from retinoic acid-induced embryoid bodies. Upon plating, these spheres yielded oligodendrocytes in a purity of >90%. The majority of these cells represented differentiated GalC-positive oligodendrocytes rather than progenitor cells. However, for applications in neural transplantation, more immature, migratory active progenitors would be preferable.
We have described previously a method for the generation of highly purified bipotential glial precursors from mouse ES cells. These precursors proliferate in the presence of FGF-2 and PDGF and, upon transplantation, give rise to astrocytes and myelinating oligodendrocytes. One of the key advantages of this differentiation paradigm is that the precursors can be obtained in unprecedented purity, a result that is best reflected in the fact that no tumor formation was noted in any of the transplant recipients (27) . Yet, only a fraction of these precursors gave rise to oligodendrocytes. After a 4 day growth factor withdrawal, <40% of the cells exhibited oligodendroglial differentiation. The remainder of the cells either expressed astrocytic marker antigens or maintained a glial precursor cell state.
In the current study, we have combined this protocol for controlled ES cell differentiation with a genetic lineage selection step. To this end, we generated mouse ES cells that express βgeo under control of the murine oligodendrocyte-specific CNP promoters I and II. CNP is one of the earliest known myelin-associated proteins synthesized in developing oligodendrocytes (59, 60) . It is expressed in two isoforms, the 46 kDa CNPI and the 48 kDa CNPII, which are generated by alternative splicing from two transcription start sites (61, 62) . Whereas CNPII is already expressed in A2B5-positive OPs, both isoforms are induced to much higher levels at later stages of oligodendroglial differentiation (63) . The early onset of CNP expression is also evident from studies on transgenic mice generated with the CNP-βgeo construct (25) . In these mice, LacZ staining was noted in brain, spinal cord, and neural crest derivatives as early as E12.5. When neural precursor cells derived from these mice were propagated in the presence of neomycine, highly purified populations of oligodendrocytes and Schwann cells could be obtained. Our data demonstrate that the application of the CNP-βgeo transgene as an oligodendroglial lineage selection tool can be translated to ES cells. Neomycine selection of glial precursors derived from CNP-βgeo ES cells yielded a population immunoreactive for A2B5, nestin, PSA-NCAM, and O4. Both A2B5 and nestin are expressed early in oligodendrogliogenesis and undergo downregulation during oligodendrocyte differentiation (31, 64, 65) . Similarly, the embryonic polysialylated form of NCAM is considered to define the precursor stage from which oligodendrocytes arise (31, (66) (67) (68) (69) (70) , although it is also expressed in other neural and non-neural cell types (71) . The NG-2 chondroitin sulfate proteoglycan, a large transmembrane glycoprotein typically expressed in OPs, but not in mature oligodendrocytes (33-35), was only detected in a small fraction of the purified cells. Numerous cells also expressed O4, an antigen detected in both proliferating pre-oligodendrocytes and mature oligodendrocytes (72, 73) . Thus, the differentiation stage of the selected cell population largely represented an early, preoligodendrocyte phenotype. In keeping with this, the selected cells were still mitotically active and amenable to FGF-2/PDGF-mediated proliferation. Upon growth factor withdrawal-induced differentiation, the vast majority of the selected cells initiated expression of GalC, a glycolipid induced during oligodendrocyte maturation. A small fraction of the selected cells was positive for GFAP, a marker not only expressed in astrocytes but also in immature and nonmyelinating SCs (74) . In principle, our lineage selection strategy should be suitable for selecting CNPpositive SCs. We, therefore, checked for the expression of Krox20 and the SC-specific myelin protein P0. The transcription factor Krox20 is induced in proliferating SC precursors, remains expressed throughout SC differentiation, and regulates the expression of a variety of SC-specific downstream genes, including P0 (36-38). The absence of Krox20 in both immunofluorescence and Western analyses and the lack of P0-immolabeled cells argue against a SC component in the purified population. Thus, the GFAP-positive cells most likely represent occasional astrocytes that had escaped neomycine selection. On the other hand, we would expect that pretreatment of the ES cell-derived precursors with factors promoting neural crest differentiation might make our method applicable for the purification of ES cell-derived SCs.
To obtain first data on potential in vivo applications of the selected OP populations, we performed transplantation experiments in md rats. This mutant has proven a particular useful model to study the myelinogenic potential of oligodendroglial preparations (41). Due to the lack of endogenous myelin formation and the absence of PLP expression, donor-derived internodes can be easily detected by mere PLP immunolabeling (75) . Indeed, 2 weeks after transplantation of CNP-βgeo-selected cells into the spinal cord of 4-6-day-old md rats, we detected numerous PLP-positive profiles characteristic of myelinating oligodendrocytes. The morphology of the myelinating donor cells was indistinguishable from previous grafts involving primary oligodendrocyte precursors (75) . Although further in vivo transplantation studies are required to comprehensively study migration, differentiation, myelination, and function of the purified cells, these data indicate that a combination of controlled differentiation and CNP promoter-mediated lineage selection of ES cells can be used to isolate a proliferating population of OPs, which, upon transplantation, differentiates into myelinating oligodendrocytes. ES cell-derived OPs generated with this method may serve as an attractive donor source for pharmacological and toxicological studies, compound development and myelin repair. 
